Teneligliptin-induced polyarthritis: A case report
Published:1 October 2021
DOI: 10.4103/jod.jod_23_21
P. Agrawal,?N. Pursnani,?A. Gautam,?Boentika Singh,?Asvini Yadav
Abstract
Rationale: DPP4 inhibitors are very important armamentarium for the management of type 2 diabetes mellitus. Usually, dipeptidyl peptidase-4 (DDP-4) inhibitors are free from side effects. Patient Concern: We report a case of teneligliptin-induced polyarthritis. Diagnosis: The diagnosis is teneligliptin-induced seronegative, non-erosive, polyarthritis. Intervention: We stopped teneligliptin. Outcome: On stopping teneligliptin, arthralgia was relieved. Lesson: Acute joint pain (arthralgia)/arthritis can be an adverse effect of teneligliptin or DPP-4 inhibitors. Arthritis, as an adverse effect of teneligliptin, is first such case report to the best of our knowledge.